<code id='9F0C06E4AE'></code><style id='9F0C06E4AE'></style>
    • <acronym id='9F0C06E4AE'></acronym>
      <center id='9F0C06E4AE'><center id='9F0C06E4AE'><tfoot id='9F0C06E4AE'></tfoot></center><abbr id='9F0C06E4AE'><dir id='9F0C06E4AE'><tfoot id='9F0C06E4AE'></tfoot><noframes id='9F0C06E4AE'>

    • <optgroup id='9F0C06E4AE'><strike id='9F0C06E4AE'><sup id='9F0C06E4AE'></sup></strike><code id='9F0C06E4AE'></code></optgroup>
        1. <b id='9F0C06E4AE'><label id='9F0C06E4AE'><select id='9F0C06E4AE'><dt id='9F0C06E4AE'><span id='9F0C06E4AE'></span></dt></select></label></b><u id='9F0C06E4AE'></u>
          <i id='9F0C06E4AE'><strike id='9F0C06E4AE'><tt id='9F0C06E4AE'><pre id='9F0C06E4AE'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:fashion    Page View:62495
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In